News
9hon MSN
Q2 2025 Management View CEO Robert Barrow highlighted that MindMed remains "on track with enrollment with our three pivotal Phase III trials for our lead asset, MM120 ODT, which is being evaluated in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback